[
  {
    "ts": null,
    "headline": "Organon acquires Actemra biosimilar’s US rights from Biogen",
    "summary": "Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.",
    "url": "https://finnhub.io/api/news?id=d1b21371e99d4c062a882482d7f4dcb58233a13244be143e4d45a3c50df9c2cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743602487,
      "headline": "Organon acquires Actemra biosimilar’s US rights from Biogen",
      "id": 133670077,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.",
      "url": "https://finnhub.io/api/news?id=d1b21371e99d4c062a882482d7f4dcb58233a13244be143e4d45a3c50df9c2cb"
    }
  },
  {
    "ts": null,
    "headline": "Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease",
    "summary": "CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer’s disease. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet medical needs. “We are encoura",
    "url": "https://finnhub.io/api/news?id=522cbf978032b41af619d7e124138fb4910f328376679375164b4f8d7c4fba6a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743593400,
      "headline": "Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease",
      "id": 133666252,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer’s disease. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet medical needs. “We are encoura",
      "url": "https://finnhub.io/api/news?id=522cbf978032b41af619d7e124138fb4910f328376679375164b4f8d7c4fba6a"
    }
  },
  {
    "ts": null,
    "headline": "Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease",
    "summary": "By Colin Kellaher Biogen has won a U.S. Food and Drug Administration fast-track designation for its investigational BIIB080 therapy for the treatment of Alzheimer's disease. Biogen on...",
    "url": "https://finnhub.io/api/news?id=a501e93477d8bf0a39e72ae06a7cb9c93cd1c8d64b7b6df14e42b0f2dafdb92b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743582254,
      "headline": "Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease",
      "id": 133665926,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Biogen has won a U.S. Food and Drug Administration fast-track designation for its investigational BIIB080 therapy for the treatment of Alzheimer's disease. Biogen on...",
      "url": "https://finnhub.io/api/news?id=a501e93477d8bf0a39e72ae06a7cb9c93cd1c8d64b7b6df14e42b0f2dafdb92b"
    }
  }
]